MCDA to create an optimal conceptual framework for evaluating novel treatments in moderate-to-severe AD by establishing the most relevant health outcomes (criteria) for decision-making from all stakeholders’ perspectives (patients, clinicians and payers).
This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.